ViaCyte, Inc., announced news today that reverberated across the cell therapy community, stating it is acquiring an exclusive license to “all BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to ViaCyte.” Importantly, this news positions ViaCyte as a leader in using stem cell therapy approaches for the treatment of Type 1 diabetes.
To learn more, read the full press release from ViaCyte below. [Read more…]